

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number	100000206	Company Code	416	Fiscal Year	2012				
Doc. Date	04/19/2012	Posting Date	04/17/2012	Period	04				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 04102012 to 04172012								
1	40	100010	Cash Concentration	GEN				25,124,090.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
2	40	302044	Dist #44 PLPAH LP	GEN				25,000,000.00	DISTRIBUTION FUNDING to PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration	GEN				33,124.35	FX INTEREST DUE
4	50	107204	Invest - PPLP	GEN				25,124,090.00-	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
5	50	100010	Cash Concentration	GEN				25,000,000.00-	DISTRIBUTION FUNDING to PLP ASC. HOLDINGS LP
6	50	102233	Lucien Holdings Sarl	GEN				33,124.35-	FX INTEREST DUE
7	40	302042	Dist #42 PP Inc	GEN				62,182.00	DISTRIBUTION FUNDING 4/17/2012 to PURDUE PHARMA, I
8	40	302043	Dist #43 PLPAH Inc	GEN				61,908.00	DISTRIBUTION FUNDING 4/17/2012 to PLP ASC. HOLDING
9	50	100010	Cash Concentration	GEN				62,182.00-	DISIRIBUTION FUNDING 4/17/2012 to PURDUE PHARMA, I
10	50	100010	Cash Concentration	GEN				61,908.00-	DISTRIBUTION FUNDING 4/17/2012 to PLP ASC. HOLDING

Transfer #1: \$25,124,090 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Transfer #2b: \$62,182 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Transfer #2c: \$61,908 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Transfer #2a: \$25,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number		Company Code		Fiscal Year		Period			
Doc. Date		Posting Date		04/19/2012		04/17/2012		04	
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 04102012 to 04172012								

**Transfer #2b:** \$62,182 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			62,182.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			62,182.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number		Company Code		Fiscal Year		Period			
Doc. Date		Posting Date		04/19/2012		04/17/2012		04	
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 04102012 to 04172012								

**Transfer #2c:** \$61,908 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			61,908.00	DISTRIBUTION FUNDING 4/17/2012 from PURDUE HOLDING
2	50	107416	Invest - PH LP		GEN			61,908.00-	DISTRIBUTION FUNDING 4/17/2012 from PURDUE HOLDING

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document						
Doc. Number	100000857	Company Code	401	Fiscal Year	2012	
Doc. Date	04/19/2012	Posting Date	04/17/2012	Period	04	
Calculate Tax	<input type="checkbox"/>					
Doc. Currency	USD					
Doc. Hdr Text	CTW 04102012 to 04172012					

**Transfer #2a:** \$25,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	40	302032	Capital #32 Dist BR		GEN			25,000,000.00	DISTRIBUTION FUNDING to BR HOLDINGS ASC. LP
3	50	107416	Invest - PH LP		GEN			25,000,000.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
4	50	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING to BR HOLDINGS ASC. LP

**Transfer #3:** \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Doc.Type : SA ( G/L account document ) Normal document						
Doc. Number	100000478	Company Code	413	Fiscal Year	2012	
Doc. Date	04/19/2012	Posting Date	04/17/2012	Period	04	
Calculate Tax	<input type="checkbox"/>					
Doc. Currency	USD					
Doc. Hdr Text	CTW 04102012 to 04172012					

**Transfer #3:** \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			85,500,000.00	FUNDING from PURDUE PHARMA L.P.
2	40	100010	Cash Concentration		GEN			25,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration		GEN			1,470,000.00	FUNDING from PURDUE PHARMA L.P.
4	40	100010	Cash Concentration		GEN			655,000.00	FUNDING from PURDUE PHARMA L.P.
5	40	100010	Cash Concentration		GEN			255,000.00	FUNDING from PURDUE PHARMA L.P.
6	50	102208	Purdue Pharma L.P.		GEN			85,500,000.00	FUNDING from PURDUE PHARMA L.P.
7	50	107401	Invest. PLP Asc.Hold		GEN			25,000,000.00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
8	50	102208	Purdue Pharma L.P.		GEN			1,470,000.00	FUNDING from PURDUE PHARMA L.P.
9	50	102208	Purdue Pharma L.P.		GEN			655,000.00	FUNDING from PURDUE PHARMA L.P.
10	50	102208	Purdue Pharma L.P.		GEN			255,000.00	FUNDING from PURDUE PHARMA L.P.

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : KR ( Vendor invoice ) Normal document									
Doc. Number	1900000088	Company Code	413	Fiscal Year	2012				
Doc. Date	04/16/2012	Posting Date	04/18/2012	Period	04				
Calculate Tax	<input checked="" type="checkbox"/>								
Ref.Doc.	41612								
Doc. Currency	USD								

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN		U1	12,500,000.00-	
2	40	302026	Capital #26 Distrib.		GEN			12,500,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document									
Doc. Number	1900000089	Company Code	413	Fiscal Year	2012				
Doc. Date	04/16/2012	Posting Date	04/18/2012	Period	04				
Calculate Tax	<input checked="" type="checkbox"/>								
Ref.Doc.	41612								
Doc. Currency	USD								

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN		U1	12,500,000.00-	
2	40	302027	Capital #27 Distrib.		GEN			12,500,000.00	

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number		Company Code		Fiscal Year		Period			
Doc. Date		04/25/2012		Posting Date		04/22/2012		Period	
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 04182012 to 04222012								

Transfer #5a: \$12,500,000 transfer from Beacon Company to Coventry Technologies L.P.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102227	Rhodes Technologies		GEN			25,000,000.00	FUNDING to RHODES TECHNOLOGIES
2	50	100010	Cash Concentration		GEN			25,000,000.00-	FUNDING to RHODES TECHNOLOGIES
3	40	100010	Cash Concentration		GEN			12,500,000.00	4/28/2012 ROSEBAY MEDICAL COMPANY
4	40	100010	Cash Concentration					12,500,000.00	4/18/2012 BEACON COMPANY
5	50	301027	Capital #27Contrib.					12,500,000.00-	4/28/2012 ROSEBAY MEDICAL COMPANY
6	50	301026	Capital #26Contrib.					12,500,000.00-	4/18/2012 BEACON COMPANY

Transfer #6: \$25,000,000 transfer from Coventry Technologies L.P. to Rhodes Technologies.

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number		Company Code		Fiscal Year		Period			
Doc. Date		04/25/2012		Posting Date		04/22/2012		Period	
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 04182012 to 04222012								

Transfer #5b: \$12,500,000 transfer from Rosebay Medical Company L.P. to Coventry Technologies L.P.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100450	BOA Money Market		GEN			25,000,000.00	MIC / BofA MONEY MARKET
2	40	100010	Cash Concentration		GEN			25,000,000.00	FUNDING from COVENTRY TECHNOLOGIES, LP
3	40	100040	Chase Control ZBA		GEN			65,377.20	CONTROL DISBURSEMENT ACCOUNT FUNDING
4	40	100040	Chase Control ZBA		GEN			7,515.95	CONTROL DISBURSEMENT ACCOUNT FUNDING
5	40	100040	Chase Control ZBA		GEN			1,012.07	CONTROL DISBURSEMENT ACCOUNT FUNDING
6	50	100010	Cash Concentration		GEN			25,000,000.00-	MIC / BofA MONEY MARKET
7	50	102230	Coventry Tech. LLC		GEN			25,000,000.00-	FUNDING from COVENTRY TECHNOLOGIES, LP

Source: SAP General Ledger detail

## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

**Transfer #1:** Authorization for \$25,124,190<sup>1</sup> transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

million distribution for Rhodes Technologies. As you will see the \$25 million is to be covered by a distribution by Purdue Pharma L.P. 50/50 to Beacon Company and Rosebay Medical Company L.P. in the net amount of \$25 million (\$12.5 million each).

In accordance with the foregoing, please arrange for a distribution from Purdue Pharma L.P. in the gross amount of \$25,124,190 in the amounts indicated as follows:

Purdue Pharma L.P. Distribution	\$25,124,190
Purdue Holdings L.P. Distribution	\$25,124,190
Purdue Pharma Inc.	\$62,182
PLP Associates Holdings Inc.	\$61,908
PLP Associates Holdings L.P.	\$25,000,000
	\$25,124,190

**Transfer #3:** Authorization for \$25,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

To BR Holdings and then Partners	\$25,000,000
Beacon (50%)	\$12,500,000
Rosebay (50%)	\$12,500,000

Please let me know the value date once the transfer has been initiated.

Thanks,

Tony

Anthony M. Roncalli  
Chadbourne & Parke LLP  
30 Rockefeller Plaza, New York, NY 10112  
tel 212-408-5261 | efax 846-710-5281  
[aroncalli@chadbourne.com](mailto:aroncalli@chadbourne.com) | private fax 212-408-5587


**Transfers #2a, #2b, and #2c:** Authorization for \$25,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$62,182 transfer from Purdue Holdings L.P. to Purdue Pharma Inc. ; and \$61,908 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$25,124,090.

**Transfers #4a and #4b:** Authorization for \$12,500,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$25,000,000.

<sup>1</sup> A \$100 discrepancy exists between the authorized distribution amount of \$25,124,190 and the distribution that was recorded in SAP of \$25,124,090.

Source: Email from Chadbourne & Parke LLP to Purdue containing wire instructions, dated 4/22/2012


## Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012



AlixPartners

## **Selection 2 Rhodes Capital Contribution (2013)**

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013



Purdue

Affiliated Entity - Books and Records  
Maintained in the same SAP System as Purdue

Beacon/Rosebay

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100122322	Company Code	208	Fiscal Year	2013				
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 05272013 to 05312013								

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
129	50	100010	Cash Concentration		GEN			13,290,000.00-	MIC / BofA MONEY MARKET
130	50	100110	Lockbox Clearing		GEN			11,858,598.83-	AMERISOURCE
131	50	100010	Cash Concentration		GEN			10,049,636.00-	FUNDING to PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100122322	Company Code	208	Fiscal Year	2013				
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 05272013 to 05312013								

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100450	BOA Money Market		GEN			37,900,000.00	MIC / BofA MONEY MARKET
2	40	100010	Cash Concentration		GEN			30,000,000.00	REDEMPTION of U.S. T-BILLS
3	40	100010	Cash Concentration		GEN			18,901,827.36	MCKESSON
4	40	100010	Cash Concentration		GEN			15,913,999.76	CARDINAL HEALTH
5	40	100450	BOA Money Market		GEN			13,290,000.00	MIC / BofA MONEY MARKET
6	40	100010	Cash Concentration		GEN			11,858,598.83	AMERISOURCE
7	40	102416	Purdue Holdings LP		GEN			10,049,636.00	FUNDING to PURDUE HOLDINGS LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document							
Doc. Number	100000321	Company Code	416	Fiscal Year	2013		
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05		
Calculate Tax	<input type="checkbox"/>						
Doc. Currency	USD						
Doc. Hdr Text	CTW 05272013 to 05312013						

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,049,636.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
2	40	102401	PLP Assoc Holdings		GEN			10,000,000.00	FUNDING to PLP ASC. HOLDINGS LP
3	40	100010	Cash Concentration		GEN			1,500,000.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
4	40	102301	Purdue Pharma Inc.		GEN			24,873.00	FUNDING to PURDE PHARMA INC.
5	40	102402	PLP Assoc Holdings		GEN			24,763.00	FUNDING to PLP
6	50	102208	Purdue Pharma L.P.		GEN			10,049,636.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
7	50	100010	Cash Concentration		GEN			10,000,000.00	FUNDING to PLP
8	50	102208	Purdue Pharma L.P.		GEN			1,500,000.00	DISTRIBUTION FUNDING from PURDUE PHARMA L.P.
9	50	100010	Cash Concentration		GEN			24,873.00	FUNDING to PURDE PHARMA, INC.
10	50	100010	Cash Concentration		GEN			24,763.00	FUNDING to PLP ASC. HOLDINGS, INC.

Transfer #2b: \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Transfer #2c: \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Transfer #1: \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Transfer #2a: \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100000979	Company Code	301	Fiscal Year	2013			
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 05272013 to 05312013							

Transfer #2b: \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,873.00	FUNDING from PURDUE HOLDINGS LP
2	40	100010	Cash Concentration		GEN			2,083.33	FUNDING from COVENTRY TECHNOLOGIES, LP (llc)
3	50	102416	Purdue Holdings LP		GEN			24,873.00-	FUNDING from PURDUE HOLDINGS LP
4	50	102230	Coventry Tech. LLC		GEN			2,083.33-	FUNDING from COVENTRY TECHNOLOGIES, LP (llc)

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100000687	Company Code	402	Fiscal Year	2013			
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 05272013 to 05312013							

Transfer #2c: \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,763.00	FUNDING from PURDUE HOLDINGS LP
2	50	102416	Purdue Holdings LP		GEN			24,763.00-	FUNDING from PURDUE HOLDINGS LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document						
Doc. Number	100000921	Company Code	401	Fiscal Year	2013	
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05	
Calculate Tax	<input type="checkbox"/>					
Doc. Currency	USD					
Doc. Hdr Text	CTW 05272013 to 05312013					

Transfer #2a: \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING from PURDUE HOLDINGS LP
2	40	102413	BR Holdings Assoc LP		GEN			10,000,000.00	FUNDING to BR HOLDINGS ASC. LP
3	50	102416	Purdue Holdings LP		GEN			10,000,000.00	FUNDING from PURDUE HOLDINGS LP
4	50	100010	Cash Concentration		GEN			10,000,000.00-	FUNDING to BR HOLDINGS ASC. LP

Transfer #3: \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Doc.Type : SA ( G/L account document ) Normal document						
Doc. Number	100000583	Company Code	413	Fiscal Year	2013	
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05	
Calculate Tax	<input type="checkbox"/>					
Doc. Currency	USD					
Doc. Hdr Text	CTW 05272013 to 05312013					

Transfer #3: \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING from PLP ASC. HOLDINGS LP
2	50	102401	PLP Assoc Holdings		GEN			10,000,000.00-	FUNDING from PLP ASC. HOLDINGS LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : KR ( Vendor invoice ) Normal document							
Doc. Number	1900000170	Company Code	413	Fiscal Year	2013		
Doc. Date	05/22/2013	Posting Date	05/29/2013	Period	05		
Calculate Tax	<input checked="" type="checkbox"/>						
Ref.Doc.	52213						
Doc. Currency	USD						

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN		U1	5,000,000.00-	
2	40	302026	Capital #26 Distrib.		GEN			5,000,000.00	

Doc.Type : KR ( Vendor invoice ) Normal document							
Doc. Number	1900000171	Company Code	413	Fiscal Year	2013		
Doc. Date	05/22/2013	Posting Date	05/29/2013	Period	05		
Calculate Tax	<input checked="" type="checkbox"/>						
Ref.Doc.	52213						
Doc. Currency	USD						

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN		U1	5,000,000.00-	
2	40	302027	Capital #27 Distrib.		GEN			5,000,000.00	

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000300	Company Code	230	Fiscal Year	2013
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 05272013 to 05312013				

Transfer #5a: \$5,000,000 from Beacon Company to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			10,000,000.00	FUNDING to RHODES PHARMACEUTICALS LP
2	40	102301	Purdue Pharma Inc.		GEN			2,083.33	FUNDING to PURDUE PHARMA, INC.
3	40	102208	Purdue Pharma L.P.		GEN			255.88	FUNDING to PURDUE PHARMA L.P.
4	50	100010	Cash Concentration					10,000,000.00-	FUNDING to RHODES PHARMACEUTICALS LP
5	50	100010	Cash Concentration					2,083.33-	FUNDING to PURDUE PHARMA, INC.
6	50	100010	Cash Concentration					255.88-	FUNDING to PURDUE PHARMA L.P.
7	40	100010	Cash Concentration					5,000,000.00	5/29/2013 BEACON
8	40	100010	Cash Concentration					5,000,000.00	5/29/2013 ROSEBAY
9	50	700030	Misc. Income	9000230	GEN			5,000,000.00-	5/29/2013 BEACON
10	50	700030	Misc. Income	9000230	GEN			5,000,000.00-	5/29/2013 ROSEBAY

Transfer #6: \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

Transfer #5b: \$5,000,000 from Rosebay Medical Company L.P. to Coventry Technologies L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100007858	Company Code	250	Fiscal Year	2013
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 05272013 to 05312013				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10,000,000.00	FUNDING to PURDUE PHARMA LP

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100007858	Company Code	250	Fiscal Year	2013
Doc. Date	06/03/2013	Posting Date	05/31/2013	Period	05
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 05272013 to 05312013				

Transfer #6: \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
21	50	102230	Coventry Tech. LLC		GEN			10,000,000.00-	FUNDING to PURDUE PHARMA LP

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

Liceaga, Juan

**From:** [REDACTED]  
**Sent:** Wednesday, May 22, 2013 2:44 PM  
**To:** [REDACTED]  
**Subject:** FW: Rhodes Pharmaceuticals L.P. - \$10 Million Funding  
**Attachments:** Written Consent of General Partner of Purdue Pharma L.P.pdf; Written Consent of General Partner of PHLF.pdf; Written Consent of General Partner of PLP Associates Holdings LP.pdf; Written Consent of General Partner of BR Holdings.pdf; Written Consent of General Partner of Coventry Technologies LP.pdf

**From:** [REDACTED]  
**Sent:** Wednesday, May 22, 2013 2:43 PM  
**To:** [REDACTED]  
**Cc:** [REDACTED] Lowne, Jon; [REDACTED]  
**Subject:** FW: Rhodes Pharmaceuticals L.P. - \$10 Million Funding

[REDACTED]  
Please clear with Accounting and process.

Thank you!

[REDACTED] Finance  
Purdue Pharma L.P.  
T [REDACTED] M [REDACTED] E [REDACTED]

**From:** Roncalli, Anthony [mailto:[ARoncalli@chadbourne.com](mailto:ARoncalli@chadbourne.com)]  
**Sent:** Wednesday, May 22, 2013 2:05 PM  
**To:** [REDACTED]  
**Cc:** Baker, Stuart D.; Mahony, Edward; Lowne, Jon; [REDACTED]  
**Subject:** Rhodes Pharmaceuticals L.P. - \$10 Million Funding

Wednesday, May 22, 2013

Dear [REDACTED]

As previously discussed attached are the following signed consents in connection with the anticipated funding of \$10 million ultimately to Rhodes Pharmaceuticals L.P.:

1. Written Consent of General Partner of Purdue Pharma L.P. ("PPLP") authorizing PPLP to distribute \$10,049,636 to Purdue Holdings L.P. ("PHLP");

**Transfer #1:** Authorization for \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

**Transfer #3:** Authorization for \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

2. Written Consent of General Partner of PHLP authorizing PHLP to transfer \$24,873 to Purdue Pharma Inc., \$24,763 to PLP Associates Holdings Inc. and \$10 million to PLP Associates Holdings L.P.,

3. Written Consent of General Partner of PLP Associates Holdings L.P. authorizing PLP Associates Holdings L.P. to transfer \$10 million to BR Holdings Associates L.P. ("BR Holdings");

4. Written Consent of General Partner of BR Holdings authorizing BR Holdings to transfer \$5 million to Beacon Company and \$5 million to Rosebay Medical Company L.P.;

5. Written Consent of General Partner of Coventry Technologies L.P. ("Coventry") authorizing Coventry upon receipt of \$5 million from Beacon Company and \$5 million from Rosebay Medical Company L.P. to transfer the \$10 million to Rhodes Pharmaceuticals L.P.

**Transfers #2a, #2b, and #2c:** Authorization for \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.; and \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$10,049,636.

**Transfer #6:** Authorization for \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P. upon receipt of \$5,000,000 transfers from Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

Please send me the wire transfer instructions to the account of Coventry, and I will make arrangements with each of Beacon Company and Rosebay Medical Company L.P. to transfer the funds to Coventry upon their receipt from BR Holdings. Please also let me know the expected value date so I can give each of Beacon Company and Rosebay Medical Company L.P. a heads up as to when they will be expected to receive and transfer the funds to Coventry.

Thanks,

Tony

**Anthony M. Roncalli**  
**Chadbourne & Parke LLP**  
30 Rockefeller Plaza, New York, NY 10112  
tel 212-408-5281 | efax 646-710-5281  
aroncalli@chadbourne.com | private fax 212-408-5587

**Transfers #4a and #4b** Authorization for \$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please notify me by replying to this message and permanently delete the original and any copy of this e-mail and any printout thereof.

For additional information about Chadbourne & Parke LLP and Chadbourne & Parke (London) LLP, including a list of attorneys, please see our website at <http://www.chadbourne.com>

## Selection 2 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013

**Transfer #3:** \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

BR HOLDINGS ASSOCIATES L.P.

Written Consent of General Partner

The undersigned, BR Holdings Associates Inc. (the "General Partner"), a New York corporation and the General Partner of BR Holdings Associates L.P., a Delaware limited partnership (the "Partnership"), hereby consents to the taking of the following actions and directs that this consent be filed with the records of proceedings of the Partnership:

WHEREAS, the Partnership is to receive a distribution from PLP Associates Holdings L.P., a Delaware limited partnership ("PLP Associates"), in the amount of \$10,000,000 (the "Distribution").

NOW, THEREFORE, be it

*OK To Pay  
Edward B. Mahony*

RESOLVED, that upon receipt of the Distribution from PLP Associates, the Partnership be and it hereby ~~is authorized to distribute \$5,000,000 to Beacon Company and \$5,000,000 to Rosebay Medical Company L.P.~~

RESOLVED, that the proper officers of the General Partner be and each of them hereby is authorized and directed to make, execute and deliver, or cause to be made, executed and delivered on behalf of itself and the Partnership all such agreements, documents, instruments and other papers as they may deem necessary or appropriate to carry out the purposes and intent of the foregoing resolution.

Date: May 22, 2013

**Transfers #4a and #4b:**  
\$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000


BR HOLDINGS ASSOCIATES L.P.  
by its general partner,  
BR Holdings Associates Inc.

By   
Stuart D. Baker  
Vice President

AlixPartners

## **Selection 3 Rhodes Capital Contribution (2013)**

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013



Purdue

Affiliated Entity - Books and Records  
Maintained in the same SAP System as Purdue

Beacon/Rosebay

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100129346	Company Code	208	Fiscal Year	2013				
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 10162013 to 10232013								

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
179	50	100110	Lockbox Clearing		GEN			18,622,831.65-	MCKESSON
180	50	100110	Lockbox Clearing		GEN			14,578,759.19-	AMERISOURCE
181	50	100110	Lockbox Clearing		GEN			14,502,799.96-	CARDINAL HEALTH
182	50	100010	Cash Concentration		GEN			10,049,636.00-	FUNDING to PURDUE HOLDINGS LP

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100129346	Company Code	208	Fiscal Year	2013				
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 10162013 to 10232013								

Transfer #1: \$10,049,636  
transfer from Purdue Pharma L.P.  
to Purdue Holdings L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102416	Purdue Holdings LP		GEN			131,147,751.00	FUNDING to PURDUE HOLDINGS LP
2	40	100450	BOA Money Market		GEN			100,000,000.00	MIC / BofA MONEY MARKET
3	40	102416	Purdue Holdings LP		GEN			41,500,000.00	FUNDING to PURDUE HOLDINGS LP
4	40	100450	BOA Money Market		GEN			36,000,000.00	MIC / BofA MONEY MARKET
5	40	100010	Cash Concentration		GEN			30,000,000.00	REDEMPTION of U.S. T-BILLS
6	40	100430	Money Mkt Goldman		GEN			25,000,000.00	GOLDMAN SACHS - MONEY MARKET
7	40	100450	BOA Money Market		GEN			20,500,000.00	MIC / BofA MONEY MARKET
8	40	100010	Cash Concentration		GEN			18,622,831.65	MCKESSON
9	40	100010	Cash Concentration		GEN			14,578,759.19	AMERISOURCE
10	40	100010	Cash Concentration		GEN			14,502,799.96	CARDINAL HEALTH
11	40	102416	Purdue Holdings LP		GEN			10,049,636.00	FUNDING to PURDUE HOLDINGS LP

Source: SAP General Ledger detail

AlixPartners

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document				
Doc. Number	100000366	Company Code	416	Fiscal Year
Doc. Date	25.10.2013	Posting Date	23.10.2013	Period
Calculate Tax	<input type="checkbox"/>			
Doc. Currency	USD			
Doc. Hdr Text	CTW 10162013 to 10232013			

Transfer #1: \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

Item	PK	Account	Account short text	Tx	Amount	Text
1	40	100010	Cash Concentration		131.147.751,00	FUNDING from PURDUE PHARMA L.P.
2	40	100010	Cash Concentration	GEN	41.500.000,00	FUNDING from PURDUE PHARMA L.P.
3	40	102413	BR Holdings Assoc LP	GEN	41.500.000,00	FUNDING to BR HOLDINGS ASC. LP
4	40	100010	Cash Concentration	GEN	10.049.636,00	FUNDING from PURDUE PHARMA L.P.
5	50	102208	Purdue Pharma L.P.	GEN	131.147.751,00	FUNDING from PURDUE PHARMA L.P.
6	50	102208	Purdue Pharma L.P.	GEN	41.500.000,00	FUNDING from PURDUE PHARMA L.P.
7	50	100010	Cash Concentration	GEN	41.500.000,00	FUNDING to BR HOLDINGS ASC. LP
8	50	102208	Purdue Pharma L.P.	GEN	10.049.636,00	FUNDING from PURDUE PHARMA L.P.
9	40	302044	Dist #44 PLPAH LP	GEN	130.500.000,00	DISTRIBUTION to PLP ASC. HOLDINGS LP 10/17
10	40	302044	Dist #44 PLPAH LP	GEN	10.000.000,00	DISTRIBUTION to PLP ASCS HOLDINGS LP 10/16
11	40	302042	Dist #42 PP Inc	GEN	324.591,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/17
12	40	302043	Dist #43 PLPAH Inc	GEN	323.160,00	DISTRIBUTION to PLP ASC HOLDINGS, INC.
13	40	302042	Dist #42 PP Inc	GEN	24.873,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/16
14	40	302043	Dist #43 PLPAH Inc	GEN	24.763,00	DISTRIBUTION to PLP ASC. HOLDINGS, INC. 10/16
15	50	100010	Cash Concentration	GEN	130.500.000,00	DISTRIBUTION to PLP ASC. HOLDINGS LP 10/17
16	50	100010	Cash Concentration	GEN	10.000.000,00	DISTRIBUTION to PLP ASCS HOLDINGS LP 10/16
17	50	100010	Cash Concentration	GEN	324.591,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/17
18	50	100010	Cash Concentration	GEN	323.160,00	DISTRIBUTION to PLP ASC HOLDINGS, INC.
19	50	100010	Cash Concentration	GEN	24.873,00	DISTRIBUTION to PURDUE PHARMA, INC. 10/16
20	50	100010	Cash Concentration	GEN	24.763,00	DISTRIBUTION to PLP ASC. HOLDINGS, INC. 10/16

Transfer #2c: \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Transfer #2a: \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100001021	Company Code	301	Fiscal Year	2013			
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 10162013 to 10232013							

Transfer #2b: \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,873.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			24,873.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			324,591.00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	50	107416	Invest - PH LP		GEN			324,591.00-	DISTRIBUTION from PURDUE HOLDINGS LP 10/17

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100000720	Company Code	402	Fiscal Year	2013			
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 10162013 to 10232013							

Transfer #2c: \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			24,763.00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			24,763.00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			323,160.00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	50	107416	Invest - PH LP		GEN			323,160.00-	DISTRIBUTION from PURDUE HOLDINGS LP 10/17

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100000943	Company Code	401	Fiscal Year	2013				
Doc. Date	25.10.2013	Posting Date	23.10.2013	Period	10				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 10162013 to 10232013								

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			10.000.000,00	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
2	50	107416	Invest - PH LP		GEN			10.000.000,00-	DISTRIBUTION FUNDING from PURDUE HOLDINGS LP
3	40	100010	Cash Concentration		GEN			130.500.000,00	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
4	40	302032	Capital #32 Dist BR		GEN			130.500.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/17/2013
5	40	302032	Capital #32 Dist BR		GEN			10.000.000,00	DISTRIBUTION to BR HOLDINGS ASC. LP 10/16
6	50	107416	Invest - PH LP		GEN			130.500.000,00-	DISTRIBUTION from PURDUE HOLDINGS LP 10/17
7	50	100010	Cash Concentration		GEN			130.500.000,00-	DISTRIBUTION to BR HOLDINGS ASC. LP 10/17/2013
8	50	100010	Cash Concentration		GEN			10.000.000,00-	DISTRIBUTION to BR HOLDINGS ASC. LP 10/16

Transfer #2a: \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.

Doc.Type : SA ( G/L account document ) Normal document									
Doc. Number	100000611	Company Code	413	Fiscal Year	2013				
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10				
Calculate Tax	<input type="checkbox"/>								
Doc. Currency	USD								
Doc. Hdr Text	CTW 10162013 to 10232013								

Transfer #3: \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			41,500,000,00	FUNDING from PURDUE HOLDINGS LP
2	40	100010	Cash Concentration		GEN			10,000,000,00	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
3	50	102416	Purdue Holdings LP		GEN			41,500,000,00-	FUNDING from PURDUE HOLDINGS LP
4	50	107401	Invest. PLP Asc.Hold		GEN			10,000,000,00-	DISTRIBUTION FUNDING from PLP ASC. HOLDINGS LP
5	40	100010	Cash Concentration		GEN			130,500,000,00	DISTRIBUTION from PLP ASC. HOLDINGS LP 10/17/2013
6	50	107401	Invest. PLP Asc.Hold		GEN			130,500,000,00-	DISTRIBUTION from PLP ASC. HOLDINGS LP 10/17/2013

Transfer #3: \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : KR ( Vendor invoice ) Normal document						
Doc. Number	1900000199	Company Code	413	Fiscal Year	2013	
Doc. Date	09/24/2013	Posting Date	10/16/2013	Period	10	
Calculate Tax	<input type="checkbox"/>					
Ref.Doc.	92413					
Doc. Currency	USD					

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1029154	BEACON CO		GEN			5,000,000.00-	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING
2	40	302026	Capital #26 Distrib.		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING

Doc.Type : KR ( Vendor invoice ) Normal document						
Doc. Number	1900000200	Company Code	413	Fiscal Year	2013	
Doc. Date	09/24/2013	Posting Date	10/16/2013	Period	10	
Calculate Tax	<input type="checkbox"/>					
Ref.Doc.	92413					
Doc. Currency	USD					

Transfer #4a: \$5,000,000 transfer from BR Holdings Associates L.P. to Beacon Company.

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN			5,000,000.00-	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING
2	40	302027	Capital #27 Distrib.		GEN			5,000,000.00	PARTNER DIST. RHODES PHARMACEUTICAL FUNDING

Transfer #4b: \$5,000,000 transfer from BR Holdings Associates L.P. to Rosebay Medical Company L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100000331	Company Code	230	Fiscal Year	2013
Doc. Date	11/11/2013	Posting Date	11/06/2013	Period	11
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 11012013 to 11062013				

Transfer #5a: \$5,000,000 from Beacon Company to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			5,000,000.00	FUNDING to RHODES PHARMCEUTICALS LP
2	50	100010	Cash Concentration		GEN			5,000,000.00-	FUNDING to RHODES PHARMCEUTICALS LP
3	40	100010	Cash Concentration		GEN			5,000,000.00	11/1/2013 BEACON CO.
4	50	301026	Capital #26Contrib.					5,000,000.00-	11/1/2013 BEACON CO.

Transfer #6a: \$5,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100000324	Company Code	230	Fiscal Year	2013			
Doc. Date	10/25/2013	Posting Date	10/23/2013	Period	10			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 10162013 to 10232013							

Transfer #5b: \$5,000,000 from Rosebay Medical Company L.P. to Coventry Technologies L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING from RHODES TECHNOLOGIES (227)
2	50	102227	Rhodes Technologies		GEN			5,000,000.00-	FUNDING from RHODES TECHNOLOGIES (227)
3	40	100010	Cash Concentration		GEN			5,000,000.00	10/21/2013 ROSEBAY MEDICAL COMPANY
4	50	103040	AR Other		GEN			5,000,000.00-	10/21/2013 ROSEBAY MEDICAL COMPANY

Doc.Type : SA ( G/L account document ) Normal document								
Doc. Number	100000327	Company Code	230	Fiscal Year	2013			
Doc. Date	11/01/2013	Posting Date	10/31/2013	Period	10			
Calculate Tax	<input type="checkbox"/>							
Doc. Currency	USD							
Doc. Hdr Text	CTW 10292013 to 10312013							

Transfer #6b: \$5,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	102250	Rhodes Pharm LP		GEN			5,000,000.00	FUNDING to RHODES PHARMACEUTICALS LP
2	50	100010	Cash Concentration		GEN			5,000,000.00-	FUNDING to RHODES PHARMACEUTICALS LP

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100009240	Company Code	250	Fiscal Year	2013
Doc. Date	11/01/2013	Posting Date	10/31/2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 10292013 to 10312013				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING to PURDUE PHARMA LP
2	40	100010	Cash Concentration		GEN			294,320.04	MORRIS & DICKSON A/R RECEIPT
3	40	100010	Cash Concentration		GEN			37,604.30	INDIVIDUAL LOCKBOX DEPOSIT
4	40	100010	Cash Concentration		GEN			7,818.09	SMITH DRUG COMPANY
5	40	100010	Cash Concentration		GEN			4,798.08	INDIVIDUAL LOCKBOX DEPOSIT
6	40	100010	Cash Concentration		GEN			3,361.38	ROCHESTER DRUG
7	40	100010	Cash Concentration		GEN			2,056.94	PBA TRUECARE
8	40	100010	Cash Concentration		GEN			2,009.90	DAKOTA DRUG, INC.
9	50	102230	Coventry Tech. LLC		GEN			5,000,000.00-	FUNDING to PURDUE PHARMA LP

Transfer #6b: \$5,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100009359	Company Code	250	Fiscal Year	2013
Doc. Date	11/11/2013	Posting Date	11/06/2013	Period	11
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Doc. Hdr Text	CTW 11012013 to 11062013				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			5,000,000.00	FUNDING to PURDUE PHARMA LP
2	40	100010	Cash Concentration		GEN			691,969.75	MORRIS & DICKSON A/R RECEIPT
3	40	100010	Cash Concentration		GEN			40,685.60	INDIVIDUAL LOCKBOX DEPOSIT
4	40	100010	Cash Concentration					24,167.86	SMITH DRUG COMPANY
5	40	100010	Cash Concentration					20,998.19	INDIVIDUAL LOCKBOX DEPOSIT
6	40	100010	Cash Concentration					12,031.86	ROCHESTER DRUG
7	40	100010	Cash Concentration					6,620.64	INDIVIDUAL LOCKBOX DEPOSIT
8	40	100010	Cash Concentration					2,205.94	HARVARD DRUG GRP.
9	40	100010	Cash Concentration		GEN			1,262.94	INDIVIDUAL LOCKBOX DEPOSIT
10	40	100010	Cash Concentration		GEN			357.90	NC MUTUAL DRUG
11	50	102230	Coventry Tech. LLC		GEN			5,000,000.00-	FUNDING to PURDUE PHARMA LP

Transfer #6a: \$5,000,000  
transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P.

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013

**Transfer #1:** Authorization for \$10,049,636 transfer from Purdue Pharma L.P. to Purdue Holdings L.P.

**Transfer #3:** Authorization for \$10,000,000 transfer from PLP Associates Holdings L.P. to BR Holdings Associates L.P.

**Transfers #6a and #6b:** Authorization for \$10,000,000 transfer from Coventry Technologies L.P. to Rhodes Pharmaceuticals L.P. upon receipt of \$5,000,000 transfers from Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000

From: McClatchey, Ian [mailto:[McClatchey@chadbourne.com](mailto:McClatchey@chadbourne.com)]

Sent: Tuesday, September 10, 2013 8:24 PM

To: [REDACTED]

Cc: Baker, Stuart D.; Mahony, Edward; Lowrie, Jon; [REDACTED]

Quinn-Felice, Jennifer

Roncalli, Anthony;

**Subject:** Rhodes Pharmaceuticals L.P. - \$10 Million Funding

Tuesday, September 10, 2013

Dear [REDACTED]

Attached are the following signed consents in connection with the anticipated funding of \$10 million ultimately to Rhodes Pharmaceuticals L.P.:

1. Written Consent of General Partner of Purdue Pharma L.P. ("PPLP") authorizing PPLP to distribute \$10,049,636 to Purdue Holdings L.P. ("PHLP");
2. Written Consent of General Partner of PHLP authorizing PHLP to transfer \$24,873 to Purdue Pharma Inc., \$24,763 to PLP Associates Holdings Inc. and \$10 million to PLP Associates Holdings L.P.;
3. Written Consent of General Partner of PLP Associates Holdings L.P. authorizing PLP Associates Holdings L.P. to transfer \$10 million to BR Holdings Associates L.P. ("BR Holdings");
4. Written Consent of General Partner of BR Holdings authorizing BR Holdings to transfer \$5 million to Beacon Company and \$5 million to Rosebay Medical Company L.P.; and
5. Written Consent of General Partner of Coventry Technologies L.P. ("Coventry") authorizing Coventry upon receipt of \$5 million from Beacon Company and \$5 million from Rosebay Medical Company L.P. to transfer the \$10 million to Rhodes Pharmaceuticals L.P.

**Transfers #2a, #2b, and #2c:** Authorization for \$10,000,000 transfer from Purdue Holdings L.P. to PLP Associates Holdings L.P.; \$24,873 transfer from Purdue Holdings L.P. to Purdue Pharma Inc. ; and \$24,763 transfer from Purdue Holdings L.P. to PLP Assoc Holdings Inc. totaling \$10,049,636.

**Transfers #4a and #4b:** Authorization for \$5,000,000 transfers from BR Holdings Associates L.P. to Beacon Company and Rosebay Medical Company L.P., totaling \$10,000,000


I will make arrangements with each of Beacon Company and Rosebay Medical Company L.P. to transfer the funds to Coventry's JPMorgan account ending in [REDACTED] upon their receipt from BR Holdings. Please let me know the expected value date so I can give each of Beacon Company and Rosebay Medical Company L.P. a heads up as to when they will be expected to receive and transfer the funds to Coventry.

Please do not hesitate to contact me if you have any questions or if I may be of any assistance regarding this funding request.

Thank you,

Ian

## Selection 3 – Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013



Source: Written consent of BR Holdings Associates L.P. General Partner, dated 9/10/2013

AlixPartners

## **Exhibit G – Analysis of Distributions Referenced in the State Complaints Filed Against Purdue and/or the Sackler Family Members**

## Exhibit G – Analysis of Distributions Referenced in Complaints, Objectives and Procedures Performed

### Objectives

1. Review State Complaints filed against Purdue and/or Sackler Family members to identify allegations of distributions made by Purdue to or for the benefit of the Affiliated Entities.
2. Assess whether the distributions alleged in the State Complaints were or appear to have been included in Purdue's Internal Distribution Analysis and reconcile potential discrepancies.

### Procedures Performed

1. Reviewed State Complaints filed against Purdue and/or Sackler Family members and identified the allegations of distributions made by Purdue to Affiliated Entities.

State	Original/Amended	Date of Complaint
Connecticut	Amended	May 6, 2019
Indiana	Original	May 21, 2019
Iowa	Original	May 16, 2019
Kansas	Original	May 16, 2019
Maryland	Original	May 16, 2019
Massachusetts	Amended	January 31, 2019
New Jersey	Original	May 30, 2019
New York	Amended	March 28, 2019
Oklahoma	Original	June 30, 2017
Oregon	Original	September 18, 2018
Pennsylvania	Original	May 15, 2019
West Virginia	Original	May 16, 2019
Wisconsin	Original	May 16, 2019

2. Quantified the dollar amounts of the distributions made by Purdue to Affiliated Entities as alleged in the State Complaints.
3. Reconciled the distributions made by Purdue to Affiliated Entities as alleged in the State Complaints to the distributions included in Purdue's Internal Distribution Analysis.

## Exhibit G - Analysis of Distributions Referenced in Complaints - Observations and Findings

1. For many of the distribution amounts alleged in the State Complaints, we identified either exact or similar dollar amounts at or around the same time period that were included in Purdue's Internal Distribution Analysis.
  - For identification of either exact or similar dollar amounts at or around the same time period, we assumed that those distributions referenced in the State Complaints were included in Purdue's Internal Distribution Analysis.
2. The State Complaints alleged inexact amounts and did not always provide sufficiently detailed information and/or references to supporting documentation in order to assess whether those distributions were included in Purdue's Internal Distribution Analysis.
  - We did not find any instances where distribution amounts alleged in the State Complaints during a particular time period exceeded distributions amounts reported in Purdue's Internal Distribution Analysis for that same time period.

## Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

- The following tables illustrates that the annual distribution amounts reported in Purdue's Internal Distribution Analysis exceeded the alleged distributions that were included in the State Complaints aggregated by year.
  - The following pages identified which individual distributions that were alleged in the State Complaints have been identified in Purdue's Internal Distribution Analysis. The remaining distributions in the State Complaints have been included in the column name "Complaints Unidentified Individual Distributions."
  - After taking into account the Unidentified Individual Distributions, the total annual distributions reported in Purdue's Internal Distribution Analysis exceeded all of the distributions that were alleged in the State Complaints for that same year.

Year	Complaints	Purdue's Internal Distribution Analysis	Complaints Sum of Individual Distributions by Year	Complaints Unidentified Alleged Distributions	Complaints Total Distributions
2008	MA, CT	\$ 1,292,135,359	\$ 1,125,000,000	\$ -	\$ 1,125,000,000
2009	MA	1,594,762,000	535,000,000	-	535,000,000
2010	MA	1,626,663,503	877,650,000	11,350,000	889,000,000
2011	MA	1,254,856,650	530,500,000	20,500,000	551,000,000
2012	MA, CT	1,057,103,806	242,000,000	176,200,000	418,200,000
2013	MA, CT, IN	953,850,252	59,930,000	339,990,000	399,920,000
2014	CT	832,658,451	73,367,059	89,632,941	163,000,000
2015	CT	906,330,390	205,358,000	-	205,358,000
2016	CT	566,875,000	107,000,000	69,142,000	176,142,000
<b>2008-2016 MA,CT,IN</b>	<b>\$ 10,085,235,411</b>	<b>\$ 3,755,805,059</b>	<b>\$ 706,814,941</b>	<b>\$ 4,462,620,000</b>	

## Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

**Reconciliation of Distributions Listed in State Complaints to Purdue's Internal Distribution Analysis, Page 1 of 2**

Result	Complaints Individual Distributions	Complaints Unidentified Alleged Distributions	Total Distributions Amount	Period	Complaints	Page	¶
In Purdue's Internal Distribution Analysis	\$ 250,000,000	\$ -	\$ 250,000,000	2008 MA	81	242	
In Purdue's Internal Distribution Analysis	325,000,000	-	325,000,000	2008 MA	83	251	
In Purdue's Internal Distribution Analysis	275,000,000	-	275,000,000	2008 CT	42	153	
In Purdue's Internal Distribution Analysis	275,000,000	-	275,000,000	2008 CT	42	153	
Year: 2008	\$ 1,125,000,000	\$ -	\$ 1,125,000,000				
In Purdue's Internal Distribution Analysis	\$ 200,000,000	\$ -	\$ 200,000,000	2009 MA	83	253	
In Purdue's Internal Distribution Analysis	162,000,000	-	162,000,000	2009 MA	85	259	
In Purdue's Internal Distribution Analysis	173,000,000	-	173,000,000	2009 MA	87	265	
Year: 2009	\$ 535,000,000	\$ -	\$ 535,000,000				
In Purdue's Internal Distribution Analysis	\$ 236,650,000	\$ -	\$ 236,650,000	2010 MA	97	292	
In Purdue's Internal Distribution Analysis	141,000,000	-	141,000,000	2010 MA	98	295	
In Purdue's Internal Distribution Analysis	260,000,000	-	260,000,000	2010 MA	110	327	
In Purdue's Internal Distribution Analysis	240,000,000 <sup>1</sup>	-	240,000,000	2010 MA	108	320	
Sum of Multiple Distributions Exceeds Complaint	-	11,350,000	11,350,000	2010 MA	113	336	
Year: 2010	\$ 877,650,000	\$ 11,350,000	\$ 889,000,000				
In Purdue's Internal Distribution Analysis	\$ 189,700,000	\$ -	\$ 189,700,000	2011 MA	115	340	
In Purdue's Internal Distribution Analysis	200,000,000	-	200,000,000	2011 MA	121	357	
In Purdue's Internal Distribution Analysis	140,800,000	-	140,800,000	2011 MA	122	363	
Sum of Multiple Distributions Exceeds Complaint	-	20,500,000	20,500,000	2011 MA	123	365	
Year: 2011	\$ 530,500,000	\$ 20,500,000	\$ 551,000,000				
In Purdue's Internal Distribution Analysis	\$ 129,000,000	\$ -	\$ 129,000,000	2012 MA	265	866	
In Purdue's Internal Distribution Analysis	113,000,000	-	113,000,000	2012 CT	42	153	
Sum of Multiple Distributions Exceeds Complaint	-	176,200,000	176,200,000	2012 MA	265	886	
Year: 2012	\$ 242,000,000	\$ 176,200,000	\$ 418,200,000				

<sup>1</sup> The \$240 million distribution in 2010 includes a \$30 million distribution from Millsaw Realty L.P., apparently made at the direction of Purdue. The \$30 million distribution was not included in Purdue's combined audited financial statements, Internal Distributions Analysis or the October 19, 2018 MDL Presentation.

## Exhibit G - Reconciled Distributions Alleged in State Complaints to Purdue's Internal Distribution Analysis

Reconciliation of Distributions Listed in State Complaints to Purdue's Internal Distribution Analysis, Page 2 of 2

Result		Complaints Individual Distributions	Complaints Unidentified Alleged Distributions	Total Distributions Amount	Period	Complaints	Page	¶
In Purdue's Internal Distribution Analysis	\$	2,930,000	\$ -	\$ 2,930,000	2013	CT	41	151
In Purdue's Internal Distribution Analysis		15,000,000	-	15,000,000	2013	CT	42	152
In Purdue's Internal Distribution Analysis		42,000,000	-	42,000,000	2013	IN	95	313
Sum of Multiple Distributions Exceeds Complaint		-	339,990,000	339,990,000	2013	MA	143	421
Year: 2013	\$	59,930,000	\$ 339,990,000	\$ 399,920,000				
In Purdue's Internal Distribution Analysis	\$	367,059	\$ -	\$ 367,059	2014	CT	41	151
In Purdue's Internal Distribution Analysis		57,400,000	-	57,400,000	2014	CT	41	151
In Purdue's Internal Distribution Analysis		15,600,000	-	15,600,000	2014	CT	41	151
Sum of Multiple Distributions Exceeds Complaint		-	89,632,941	89,632,941	2014	CT	42	154
Year: 2014	\$	73,367,059	\$ 89,632,941	\$ 163,000,000				
In Purdue's Internal Distribution Analysis	\$	710,500	\$ -	\$ 710,500	2015	CT	41	151
In Purdue's Internal Distribution Analysis		2,160,000	-	2,160,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis		135,000,000	-	135,000,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis		1,975,000	-	1,975,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis		60,000,000	-	60,000,000	2015	CT	41	151
In Purdue's Internal Distribution Analysis		5,512,500	-	5,512,500	2015	CT	42	152
Year: 2015	\$	205,358,000	\$ -	\$ 205,358,000				
In Purdue's Internal Distribution Analysis	\$	107,000,000	\$ -	\$ 107,000,000	2016	CT	41	151
Sum of Multiple Distributions Exceeds Complaint		-	69,142,000	69,142,000	2016	CT	42	154
Year: 2016	\$	107,000,000	\$ 69,142,000	\$ 176,142,000				
	\$	3,755,805,059	\$ 706,814,941	\$ 4,462,620,000	2008-2016			

AlixPartners

## **Exhibit H - Pension Benefits Detailed Procedures Performed**

## Exhibit H - Pension Benefits, Detailed Procedures Performed

In order to achieve the objectives of the Pension Benefits Analysis, we performed the following procedures:

1. Obtained Purdue's Pension Plan document and other relevant information from Purdue for the purposes of quantifying the amount of Pension Benefits paid or owed to the Sackler Family members.
2. Identified the Sackler Family members referenced in these documents who received Pension Benefits or will become eligible to receive Pension Benefits.
3. Confirmed with Purdue's Director of Benefits and HRIS that no other Sackler Family members were or are eligible for Pension Benefits under Purdue's Pension Plan.
4. Reviewed and analyzed Deloitte's Pension Benefit calculation worksheets.
5. Reviewed Purdue's Pension Plan document in order to determine if the Sackler Family members who have been paid out under Purdue's Pension Plan as well as those who will receive future benefits appear eligible as defined in Purdue's Pension Plan document.

AlixPartners

## **Exhibit I - Travel and Expense Reimbursements Detailed Procedures Performed**

## Exhibit I – T&E Reimbursements, Detailed Procedures Performed

In order to achieve the objectives of the T&E Spend Analysis, we performed the following procedures:

1. Requested T&E report-level data for all Purdue T&E reimbursements paid on or after January 1, 2008 from Purdue's Controller and Assistant Manager of Corporate Travel.
  - Purdue was the only Purdue entity that paid T&E reimbursements to or on behalf of the Sackler Family members.
  - Purdue had records available for T&E reimbursements submitted through the current T&E system, Databasics, starting in April 2011. T&E reimbursement information prior to April 2011 has been archived and was not available.
2. Identified the Sackler Family members who submitted expense reports in Purdue's T&E system, Databasics, which went live in April 2011. No T&E reimbursements had been submitted by or paid to the Sackler Family members through the T&E reporting system after December 31, 2018.
3. Requested individual line-item detail within expense reports for the Sackler Family members from Purdue's Assistant Manager of Corporate Travel. Reviewed transactions and summarized expenses by year, expense category (as defined by Purdue), Sackler Family member name, and reimbursement type (paid American Express company credit card vs. reimbursed a Sackler Family member directly).<sup>1</sup>
  - Expense categories were taken directly from Purdue's T&E reporting system and relied on.
  - Reviewed receipts/supporting documentation submitted through Databasic with T&E reports for approximately 73% of the total dollar amount of reimbursements made to or for the benefit of the Sackler Family members. Criteria used for selections can be found on the following page.
    - o Selected 343 items included in the T&E reports totaling approximately \$849,000 to determine if the expense reports contained documentation supporting the T&E reimbursements.
    - o Of the 343 expenses selected, 341 (or 99.4%) items included underlying receipts/supporting documentation. This represented 99.97% of the total dollar amount of T&E reimbursements selected for review.
  - No assessment of the business reasonableness of the expenses was made.
  - No assessment of whether expenses were in compliance with Purdue's T&E policies was made.

---

<sup>1</sup> Sackler Family members were issued American Express Corporate Credit Cards in their own names, which Purdue paid directly to American Express upon submission of expense reports. Purdue also issued Procurement Cards to various employees, however, none were issued to Sackler Family members.

## Exhibit I – T&E Reimbursements, Detailed Procedures Performed

4. Criteria for selecting the receipts/supporting documentation from Purdue's T&E reporting system for review was as follows:

Category	Selection Criteria	
Airline	Amounts over \$5,000	
HCP (Health Care Professional)	Amounts over \$500	
Hotel	Due to Employee	Amounts over \$500
	Due to Card	Amounts over \$1,000
Meals (Self)	Due to Employee	Amounts over \$100
	Due to Card	Amounts over \$100
Meals and Entertainment	Due to Employee	Amounts over \$500
	Due to Card	Amounts over \$500
Taxi/Car/Ground Transportation	Due to Employee	Amounts over \$400
	Due to Card	Amounts over \$400
Miscellaneous	Due to Employee	Amounts over \$300
	Due to Card	Amounts over \$300

5. Identified payments made directly to the Sackler Family members recorded as T&E reimbursements in Purdue's SAP accounts payable ledger on or after January 1, 2008. No T&E reimbursements had been submitted by or paid to the Sackler Family members through accounts payable after March 31, 2019.

## Exhibit I – T&E Reimbursements, Detailed Procedures Performed

6. Reviewed documentation in SAP supporting T&E reimbursements paid through accounts payable, and assigned an expense category to each T&E reimbursement to the extent sufficient detail was available in Purdue's SAP accounting system.
  - Purdue's SAP accounting system included invoices, other supporting documentation and/or descriptions for approximately 87% of the total dollar amount of T&E reimbursements paid to the Sackler Family members through accounts payable.
7. Obtained and reviewed Purdue's Travel Policy and Procedures in effect during the years 2008 through 2018.
8. Held meetings and/or communicated with Purdue employees regarding the T&E policy and reimbursement process and to gain an understanding of the accounting for and quantification of T&E reimbursements paid by Purdue.
  - A list of the Purdue employees we met with and/or communicated with about T&E reimbursements is included in Appendix A.